Patients with Type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial presented at the European Society of Cardiology Congress.
Fuente : http://www.eurekalert.org/pub_releases/2013-09/eso...
Fuente : http://www.eurekalert.org/pub_releases/2013-09/eso...